ASH 2025 | Updated data on zanubrutinib plus sonrotoclax combination as a first-line treatment for CLL

So we are updating the data on the sonrotoclax plus zanubrutinib as first-line treatment for CLL. And this is a subset of patients treated in the sonrotoclax phase one study. So in all, we’ve got now over 130 patients receiving the combination, so zanubrutinib oral sonrotoclax oral, no intravenous infusions as first-line therapy for CLL. Some years ago, we reported the initial MRD rates for this combination, and the MRD rate looks like as if it was going to be over 90%, but on very few numbers. So we wanted to confirm that with further follow-up, and now with two further years of follow-up, we can report the best MRD rate is indeed over 90%. In fact, it’s 94%. And in the 320 milligram cohort, which is the phase two dose, we have not had a single relapse so far. So, so far we now have over 130 patients. We’ve confirmed that this is a targeted combination with two targeted drugs, both oral, and we’re now getting an MRD clearance rate, which is actually the highest MRD clearance rate of any CLL drug developed to date. This study has now been studied in a randomized phase three against venetoclax and obinutuzumab in a study called CELESTIAL. CELESTIAL has fully recruited and hopefully the phase three study will confirm the favorable data from phase one.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.